MedTrace Logo

Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy

NCT07153614 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-09-04

No results posted yet for this study

Summary

The primary purpose of this study is to determine if intrathecal morphine (ITM) administration is superior to quadratus lumborum block or surgeon administered transversus abdominis plane (TAP) blocks result in decreased time to initiation of chemotherapy following oncologic surgery.

The secondary objectives of this study are to determine:

* The difference between interventions in time to return of bowel function in days
* The difference between interventions in incidence of opioid related adverse drug events (ORADEs)
* The difference between interventions in cumulative and post-operative total morphine milligram equivalents
* The difference between interventions in quality-of-life assessment tool and patient satisfaction (brief pain index short form BPI-sf9)
* The difference between interventions in hospital length of stay in days
* The difference between cumulative pain scores between interventions
* The difference between short acting and long-acting bupivacaine in pain management and time to chemotherapy

The hypothesis is that preoperative intrathecal morphine administration will significantly reduce the time to initiation of postoperative chemotherapy.

Conditions

  • Perioperative Opioid Sparing Techniques

Interventions

PROCEDURE

Intrathecal Morphine Block

Morphine 150 mcg

PROCEDURE

Bilateral Quadratus Lumborum Block

30 mL of 0.25% bupivacaine and 4mg of dexamethasone

PROCEDURE

Bilateral Transverse Abdominis Plane Block

Exparel-based solution mixed with 50mL of saline

Sponsors & Collaborators

  • University of Tennessee Graduate School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-03
Primary Completion
2027-02-03
Completion
2027-02-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07153614 on ClinicalTrials.gov